Outcome Of Unrelated Donor Blood And Marrow Transplantation (BMT) For Children With Acute Lymphoblastic Leukemia (ALL) In Third Remission

Eneida R. Nemecek(Oregon Health & Science University), Haydar Frangoul(Children’s Hospital at TriStar Centennial), Stella M. Davies(Cincinnati Children's Hospital Medical Center), Mary Eapen(Medical College of Wisconsin), Ann E. Woolfrey(University of Washington), Adriana Seber(Support group for adolescents and children with cancer), Wanzhong He(Medical College of Wisconsin), Kristin Ellis, M.L. MacMillan(University of Minnesota Medical Center), Paul A. Carpenter(Fred Hutch Cancer Center)
Transplantation and Cellular Therapy
February 1, 2010
10.1016/j.bbmt.2009.12.266
Cited by 1

Related Papers

Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
|New England Journal of Medicine|2018|5.7k
CRISPR-Cas9 Gene Editing for Sickle Cell Disease and β-Thalassemia
|New England Journal of Medicine|2020|1.8k
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
|Nature Medicine|2018|577
Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases
|Blood|2003|457